{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T00:17:08Z","timestamp":1720311428040},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,7,1]]},"DOI":"10.2169\/internalmedicine.2799-23","type":"journal-article","created":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T22:15:28Z","timestamp":1719785728000},"page":"1917-1922","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent Cerebral Hemorrhaging with Platelet Dysfunction Accompanied by Anti-glycoprotein VI Autoantibodies in a Patient with TAFRO Syndrome"],"prefix":"10.2169","volume":"63","author":[{"given":"Akira","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisakazu","family":"Nishimori","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Clinical and Laboratory Medicine, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Takano","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine and Cell Therapy, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Komura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Okayama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Kambara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Fukumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Urata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Clinical Laboratory, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"},{"name":"Department of Blood Transfusion, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Niiya","sequence":"additional","affiliation":[{"name":"Junpukai Health Maintenance Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsue","family":"Suzuki-Inoue","sequence":"additional","affiliation":[{"name":"Department of Clinical and Laboratory Medicine, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91: 220-226, 2016.","DOI":"10.1002\/ajh.24242"},{"key":"2","unstructured":"2. Takai K, Nikkuni K, Shibuya H, Hashidate H. [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. Rinsho Ketsueki (Jpn J Clin Hematol) 51: 320-325, 2010 (in Japanese)."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI\/FcR\u03b3-chain complex from the human platelet surface. Blood 104: 1350-1355, 2004.","DOI":"10.1182\/blood-2004-03-0896"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 84: 1440-1445, 1989.","DOI":"10.1172\/JCI114318"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 1: 485-491, 2003.","DOI":"10.1046\/j.1538-7836.2003.00091.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 139: 363-372, 2007.","DOI":"10.1111\/j.1365-2141.2007.06799.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103: 686-692, 2016.","DOI":"10.1007\/s12185-016-1979-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Masaki Y, Kawabata H, Takai K, et al. 2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111: 155-158, 2020.","DOI":"10.1007\/s12185-019-02780-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Suzuki-Inoue K, Tulasne D, Shen Y, et al. Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem 277: 21561-21566, 2002.","DOI":"10.1074\/jbc.M201012200"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kojima H, Moroi M, Jung SM, et al. Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost 4: 2433-2442, 2006.","DOI":"10.1111\/j.1538-7836.2006.02173.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kashiwagi H, Akiyama M, Tomiyama Y. [Autoantibodies and Platelet Dysfunction]. Nihon Kessen Shiketsu Gakkaishi (Jpn J Thromb Hemost) 21: 271-277, 2010 (in Japanese).","DOI":"10.2491\/jjsth.21.271"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sakashita K, Murata K, Takamori M. TAFRO syndrome: current perspectives. J Blood Med 9: 15-23, 2018.","DOI":"10.2147\/JBM.S127822"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Morita K, Fujiwara SI, Ikeda T, et al. TAFRO syndrome with an anterior mediastinal mass and lethal autoantibody-mediated thrombocytopenia: an autopsy case report. Acta Haematol 141: 158-163, 2019.","DOI":"10.1159\/000492743"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kikuchi T, Shimizu T, Toyama T, Abe R, Okamoto S. Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide. Intern Med 56: 2205-2211, 2017.","DOI":"10.2169\/internalmedicine.8522-16"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fujiki T, Hirasawa S, Watanabe S, Iwamoto S, Ando R. Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome. CEN Case Rep 6: 105-110, 2017.","DOI":"10.1007\/s13730-017-0253-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Konishi Y, Takahashi S, Nishi K, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman's disease, with cyclosporine A: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med 236: 289-295, 2015.","DOI":"10.1620\/tjem.236.289"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mizuno H, Sekine A, Oguro M, et al. Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol 82: 258-263, 2018.","DOI":"10.1016\/j.humpath.2018.03.021"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/13\/63_2799-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T03:34:48Z","timestamp":1720236888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/13\/63_2799-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":17,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2799-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"2799-23"}}